Last reviewed · How we verify
A Multicenter, Pragmatic Randomized, Double-blind, Placebo-controlled Trial of Xuezhikang Capsule for Treating Dyslipidemia: a Postmarketing Study
Dyslipidemia contributes greatly to the formation and progression of atherosclerosis (AS), which plays a dominant role in leading to CHD. Xuezhikang is a partially purified extract of fermented red yeast rice (Monascus purpureus). It is composed of 13 kinds of natural statins, unsaturated fatty acids, ergosterol,amino acids, flavonoids, alkaloid, trace element, and so forth. Xuezhikang has been recommended in a guideline for China adult dyslipidemia prevention. This study aims to evaluate the benefit and side effect of Xuezhikang, a potential alternative drug of statins, for patients with dyslipidemia, and thus provide further evidence for clinical application.
Details
| Lead sponsor | China Academy of Chinese Medical Sciences |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 2400 |
| Start date | 2010-03 |
Conditions
- Dyslipidemia
Interventions
- Xuezhikang capsule
Primary outcomes
- Blood samples were drawn were detected,including TC,TG,LDL-C and HDL-C — the detect the change from baseline to the 8th week